Pages that link to "Q33490139"
Jump to navigation
Jump to search
The following pages link to 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients (Q33490139):
Displaying 10 items.
- Neuroblastoma: solving a biologic puzzle (Q33368528) (← links)
- State of the art of therapy in nuclear medicine (Q34074381) (← links)
- Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma (Q34424834) (← links)
- Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". (Q35880923) (← links)
- Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma. (Q36353230) (← links)
- Where are we with nuclear medicine in pediatrics? (Q40961319) (← links)
- Tumour identification using radiopharmaceuticals (Q41640876) (← links)
- Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma (Q42177470) (← links)
- High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma (Q43947318) (← links)
- Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection (Q70840913) (← links)